aTen Therapeutics Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
aTen Therapeutics General Information
Description
Developer of novel therapeutic antibodies designed to offer treatment for major diseases. The company's antibodies block cancer cell growth, invasion, and metastasis in a variety of tumor models with the help of anti-cancer agents for cancer cell proliferation, tumor invasion, and metastasis, enabling doctors to improve the lives of people with cancer and protect against developing metastases.
Contact Information
Website
www.atentherapeutics.comCorporate Office
- 1 Lochrin Square
- Fountainbridge
- Edinburgh EH3 9QA
- Scotland, United Kingdom
Corporate Office
- 1 Lochrin Square
- Fountainbridge
- Edinburgh EH3 9QA
- Scotland, United Kingdom
aTen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 11-Jul-2024 | Completed | Generating Revenue | |||
| 6. Later Stage VC | Completed | Generating Revenue | ||||
| 5. Grant | 01-May-2022 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 3. Later Stage VC | 31-Mar-2017 | Completed | Generating Revenue | |||
| 2. Grant | 01-May-2016 | $143K | $429K | Completed | Generating Revenue | |
| 1. Angel (individual) | 16-Aug-2007 | $429K | $429K | Completed | Startup |
aTen Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
aTen Therapeutics Patents
aTen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202414714-D0 | Antibody and its medical uses | Inactive | 07-Oct-2024 | ||
| GB-202414702-D0 | Therapeutic use of antibody | Inactive | 07-Oct-2024 | ||
| GB-202216202-D0 | Antibody and its medical uses | Inactive | 01-Nov-2022 | ||
| GB-202216204-D0 | Therapeutic use of antibody | Inactive | 01-Nov-2022 | ||
| GB-202206195-D0 | Antibody | Inactive | 28-Apr-2022 |
aTen Therapeutics Signals
aTen Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Innovate UK | Government |
aTen Therapeutics FAQs
-
When was aTen Therapeutics founded?
aTen Therapeutics was founded in 2005.
-
Where is aTen Therapeutics headquartered?
aTen Therapeutics is headquartered in Edinburgh, United Kingdom.
-
What is the size of aTen Therapeutics?
aTen Therapeutics has 4 total employees.
-
What industry is aTen Therapeutics in?
aTen Therapeutics’s primary industry is Biotechnology.
-
Is aTen Therapeutics a private or public company?
aTen Therapeutics is a Private company.
-
What is aTen Therapeutics’s current revenue?
The current revenue for aTen Therapeutics is .
-
How much funding has aTen Therapeutics raised over time?
aTen Therapeutics has raised $2.09M.
-
Who are aTen Therapeutics’s investors?
Innovate UK has invested in aTen Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process